What are the secondary causes of immune thrombocytopenia (ITP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Secondary Causes of ITP

Secondary ITP can result from autoimmune disorders, infections, lymphoproliferative diseases, medications, and other immune-mediated conditions that must be systematically excluded when evaluating thrombocytopenia. 1

Major Categories of Secondary ITP

The American Society of Hematology guidelines provide a comprehensive list of secondary causes that should be considered in all patients presenting with immune thrombocytopenia 1, 2:

Autoimmune Disorders

  • Systemic lupus erythematosus (SLE) - one of the most common autoimmune associations
  • Antiphospholipid syndrome - can present with thrombocytopenia as an isolated finding
  • Evans syndrome - autoimmune thrombocytopenia occurring with concurrent autoimmune hemolytic anemia
  • Autoimmune thyroid disease (particularly hypothyroidism, which was found to be the most common secondary cause in one large cohort at 21.5%) 3
  • Common variable immune deficiency

Infectious Causes

The guidelines specifically highlight several infections requiring targeted evaluation and treatment:

  • Helicobacter pylori - ASH recommends screening for H. pylori in patients with ITP where eradication therapy would be used if positive (grade 2C), and that eradication therapy be administered when infection is confirmed (grade 1B) 1, 2. This was the second most common secondary cause (11.4%) in recent studies 3

  • HIV infection - Between 6-15% of HIV-infected patients develop thrombocytopenia 4. ASH strongly recommends testing all ITP patients for HIV (grade 1A) and treating the HIV infection with antiviral therapy before other ITP treatments unless clinically significant bleeding is present (grade 1A) 2

  • Hepatitis C virus (HCV) - ASH recommends testing all ITP patients for HCV (grade 1B) 2. HCV-related thrombocytopenia can occur even without overt liver disease and antiviral therapy should be considered when contraindications are absent (grade 2C) 1

  • Cytomegalovirus (CMV)

  • Varicella zoster virus

  • Epstein-Barr virus - particularly in children with acute-onset thrombocytopenia

  • Brucellosis - relevant in endemic regions 5

Lymphoproliferative Disorders

  • Chronic lymphocytic leukemia (CLL) - a well-recognized cause where the malignant clone itself may drive immune-mediated platelet destruction 6
  • Large granular T-lymphocyte leukemia
  • Other lymphoproliferative diseases 1

Drug-Induced ITP

Medication side effects represent an important and potentially reversible cause of secondary ITP 1

Other Causes

  • Bone marrow transplantation - as a complication
  • Vaccination - particularly MMR vaccine in children, though this typically presents as acute thrombocytopenia 1
  • COVID-19 infection - emerging data shows ITP can develop even after mild COVID-19 infection, sometimes with delayed onset during the recovery phase 7

Clinical Implications

The distinction between primary and secondary ITP matters clinically. Patients with secondary ITP tend to be older and report more fatigue, while those with primary ITP have higher rates of severe (grade 3/4) bleeding 3. The natural history, response to therapy, and management approach differ substantially between primary ITP and various secondary causes 8.

Diagnostic Approach

The 2019 ASH guidelines recommend 2:

  • Testing for HCV and HIV in all adult ITP patients (grade 1B)
  • Screening for H. pylori should be considered when eradication therapy would be pursued if positive (grade 2C)
  • Further investigations if abnormalities beyond isolated thrombocytopenia are present in blood counts or smear (grade 2C)
  • Bone marrow examination is not routinely necessary for typical ITP presentations, regardless of age (grade 2C) - this was confirmed by recent data showing baseline bone marrow examination did not detect secondary causes 3

Important Caveat

When autoimmune markers (ANA, anti-dsDNA, anticardiolipin antibodies, lupus anticoagulant) or infectious serologies are tested, positive results occur in 21-33% of ITP patients depending on the specific test 5, emphasizing the importance of systematic screening in appropriate clinical contexts rather than assuming all ITP is primary.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.